首页 | 本学科首页   官方微博 | 高级检索  
     


Incidence and causes of heparin-induced skin lesions
Authors:Marc Schindewolf  Svantje Schwaner  Manfred Wolter  Hartmut Kroll  Andreas Recke  Roland Kaufmann  Wolf-Henning Boehncke  Edelgard Lindhoff-Last  Ralf J. Ludwig
Affiliation:From the Departments of Internal Medicine, Division of Angiology (Schindewolf, Lindhoff-Last), and Dermatology (Schwaner, Wolter, Kaufmann, Boehncke, Ludwig), Hospital of the Johann Wolfgang Goethe University, Frankfurt am Main, Germany, the DRK-Blooddonorservice (Kroll), Dessau, Germany, and the Department of Dermatology (Recke), University of Lübeck, Lübeck, Germany
Abstract:

Background

Little is known about the incidence and causes of heparin-induced skin lesions. The 2 most commonly reported causes of heparin-induced skin lesions are immune-mediated heparin-induced thrombocytopenia and delayed-type hypersensitivity reactions.

Methods

We prospectively examined consecutive patients who received subcutaneous heparin (most often enoxaparin or nadroparin) for the presence of heparin-induced skin lesions. If such lesions were identified, we performed a skin biopsy, platelet count measurements, and antiplatelet-factor 4 antibody and allergy testing.

Results

We enrolled 320 patients. In total, 24 patients (7.5%, 95% confidence interval [CI] 4.7%–10.6%) had heparin-induced skin lesions. Delayed-type hypersensitivity reactions were identified as the cause in all 24 patients. One patient with histopathologic evidence of delayed-type hypersensitivity tested positive for antiplatelet-factor 4 antibodies. We identified the following risk factors for heparin-induced skin lesions: a body mass index greater than 25 (odds ratio [OR] 4.6, 95% CI 1.7–15.3), duration of heparin therapy longer than 9 days (OR 5.9, 95% CI 1.9–26.3) and female sex (OR 3.0, 95% CI 1.1–8.8).

Interpretation

Heparin-induced skin lesions are relatively common, have identifiable risk factors and are commonly caused by a delayed-type hypersensitivity reaction (type IV allergic response). (ClinicalTrials.gov trial register no. {"type":"clinical-trial","attrs":{"text":"NCT00510432","term_id":"NCT00510432"}}NCT00510432.)Hpeparin has been used as an anticoagulant for over 60 years.1 Well-known adverse effects of heparin therapy are bleeding, osteoporosis, hair loss, and immune and nonimmune heparin-induced thrombocytopenia. The incidence of heparin-induced skin lesions is unknown, despite being increasingly reported.24 Heparin-induced skin lesions may be caused by at least 5 mechanisms: delayed-type (type IV) hypersensitivity responses,2,46 immune-mediated thrombocytopenia,3 type I allergic reactions,7,8 skin necrosis9 and pustulosis.10Heparin-induced skin lesions may indicate the presence of life-threatening heparin-induced thrombocytopenia11 — even in the absence of thrombocytopenia.3 There are no data available on the incidence of heparin-induced skin lesions or their causes. Given the rising number of reports of heparin-induced skin lesions and the importance of correctly diagnosing this condition, we sought to determine the incidence of heparin-induced skin lesions.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号